Global Nivolumab Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Nivolumab Drugs Market Insights, Forecast to 2034
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer.
Global Nivolumab Drugs market is expected to reach to US$ 10530 million in 2024, with a positive growth of %, compared with US$ 9567 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Nivolumab Drugs industry is evaluated to reach US$ 15620 million in 2029. The CAGR will be 6.8% during 2024 to 2029.
The OPDIVO market is primarily driven by the growing demand for innovative immunotherapy treatments in the field of oncology. OPDIVO (nivolumab) is a checkpoint inhibitor that harnesses the immune system to fight cancer cells by blocking certain proteins that suppress the immune response. The increasing prevalence of cancer cases, coupled with the need for targeted therapies that offer improved survival rates and fewer adverse effects compared to traditional treatments, contributes to market growth. Moreover, the expanding range of approved indications for OPDIVO, including advanced melanoma, lung cancer, and other malignancies, further propels adoption. However, challenges include managing potential immune-related adverse events and addressing variations in patient responses to immunotherapy. Navigating the competitive landscape in the immunotherapy market and ensuring affordability and access to these treatments for a broader patient population pose ongoing concerns. The market's success hinges on continuous research to identify optimal treatment combinations and patient profiles for OPDIVO, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to optimize cancer treatment while addressing the evolving challenges associated with OPDIVO therapy.
Report Covers
This report presents an overview of global Nivolumab Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Nivolumab Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Bristol-Myers Squibb
Ono Pharmaceutical
Segment by Type
10ml
4ml
24ml
Retail Pharmacy
Hospital Pharmacy
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Nivolumab Drugs plant distribution, commercial date of Nivolumab Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Nivolumab Drugs introduction, etc. Nivolumab Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Nivolumab Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Nivolumab Drugs market is expected to reach to US$ 10530 million in 2024, with a positive growth of %, compared with US$ 9567 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Nivolumab Drugs industry is evaluated to reach US$ 15620 million in 2029. The CAGR will be 6.8% during 2024 to 2029.
The OPDIVO market is primarily driven by the growing demand for innovative immunotherapy treatments in the field of oncology. OPDIVO (nivolumab) is a checkpoint inhibitor that harnesses the immune system to fight cancer cells by blocking certain proteins that suppress the immune response. The increasing prevalence of cancer cases, coupled with the need for targeted therapies that offer improved survival rates and fewer adverse effects compared to traditional treatments, contributes to market growth. Moreover, the expanding range of approved indications for OPDIVO, including advanced melanoma, lung cancer, and other malignancies, further propels adoption. However, challenges include managing potential immune-related adverse events and addressing variations in patient responses to immunotherapy. Navigating the competitive landscape in the immunotherapy market and ensuring affordability and access to these treatments for a broader patient population pose ongoing concerns. The market's success hinges on continuous research to identify optimal treatment combinations and patient profiles for OPDIVO, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to optimize cancer treatment while addressing the evolving challenges associated with OPDIVO therapy.
Report Covers
This report presents an overview of global Nivolumab Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Nivolumab Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bristol-Myers Squibb
Ono Pharmaceutical
Segment by Type
10ml
4ml
24ml
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Nivolumab Drugs plant distribution, commercial date of Nivolumab Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Nivolumab Drugs introduction, etc. Nivolumab Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Nivolumab Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices